Anti Radiation Drugs Market Size

Anti-Radiation Drugs Market Overview

The Anti-Radiation Drugs Market Size was valued at USD 3.6 Billion in 2022. The Anti-radiation drugs market is projected to grow from USD 3.96 Billion in 2023 to USD 8.62 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 10.20% during the forecast period (2023 - 2032). Nuclear power expansion, radiation therapy in cancer treatment, radiation accidents and emergencies, military and defense applications, research and development, are the key market drivers enhancing the market growth.

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Anti-Radiation Drugs Market Trends

Nuclear power expansion is driving the market growth

A complex interaction of elements that highlights the growing need for protective measures in the face of increased radiation exposure is catalyzed by the expansion of nuclear power, which has a substantial impact on the market for anti-radiation medications. The building and operation of new nuclear power plants is increasing as nations strive to meet their energy needs while reducing carbon emissions. The workforce employed in various nuclear sector positions, such as engineers, technicians, and maintenance employees, is expected to grow in tandem with this increase. As they work with radioactive materials and radiation-emitting machinery, these specialists are frequently exposed to high radiation levels. As a result of this increased exposure, demand for anti-radiation medications has increased, which is essential as a defense against potential health concerns.

Public safety and emergency preparedness are once again in the spotlight as a result of the expansion of nuclear power. Nuclear power plant accidents and incidents, like the Fukushima Daiichi disaster, have highlighted the significance of effective safeguards and flexible plans. Comprehensive emergency response plans are essential, and these plans almost always contain provisions for safety precautions like anti-radiation medications. This is something that regulators and governments are emphasizing. Stockpiles of these medications are being built up close to nuclear facilities in preparation for any nuclear emergencies, guaranteeing quick access for both plant staff and the local populace in the event of a radiation release.

The market for anti-radiation medications is further fueled by the symbiotic relationship between the growth of nuclear power and the developments in nuclear medicine and research. Nuclear medicine, which includes a variety of medical procedures, uses radiation for diagnostic and therapeutic purposes. Workers in the healthcare industry frequently handle radioactive materials, potentially increasing their radiation exposure. In a similar vein, radiation dangers are a possibility for researchers working on nuclear projects. Anti-radiation medications provide a layer of protection on top of the strict safety protocols built into these disciplines to lessen these hazards.

The response to the spread of nuclear power is significantly shaped by the international regulatory standards established by institutions like the International Atomic Energy Agency (IAEA). In addition to being a question of safety, adherence to these criteria is essential for international cooperation and efforts to prevent the spread of nuclear weapons. The incorporation of anti-radiation medications into emergency response plans becomes increasingly important as countries work to satisfy these standards as a means of displaying readiness and adherence to international nuclear safety standards.

Addressing the rising global energy demand while adopting sustainable practices is closely related to expanding nuclear power. Due to its low carbon emissions, nuclear power is a desirable alternative and an essential part of the global energy balance in many nations. Within the nuclear business, new reactor development and operation result in job growth and employment prospects. A greater workforce performing a variety of jobs raises the need for protective measures, such as anti-radiation medications, to ensure the health and wellbeing of these individuals. Thus, driving the Anti-radiation drugs market revenue.

Anti-Radiation Drugs Market Segment Insights

Anti-Radiation Drugs Compound Insights

The Anti-Radiation Drugs Market segmentation, based on Compound, includes Potassium lodide (Kl), Prussian blue, DTPA (Diethylenetriamine Pentaacetate) and others. The potassium lodide (Kl) segment dominated the market in 2022. This is brought on by the substantial demand for KI pills as radiation protection. Non-radioactive iodine, which is present in KI pills, can aid in preventing the thyroid gland from absorbing radioactive iodine. This is significant because thyroid cancer can be brought on by radioactive iodine.

Anti-Radiation Drugs Application Insights

The Anti-Radiation Drugs Market segmentation, based on Application, includes Acute Radiation Syndrome (ARS), Cancer Treatment, Radiation Exposure and Others. The acute radiation syndrome (ARS) segment dominated the market in 2022. This is due to the dangerous nature of ARS, which can be lethal if untreated quickly. Anti-radiation medications are used to treat ARS symptoms such diarrhoea, nausea, vomiting, and hair loss.

Anti-Radiation Drugs Distribution channel Insights

The Anti-Radiation Drugs Market segmentation, based on distribution channel, includes Hospital Pharmacies, Retail Pharmacies and Others. The hospital pharmacies category generated the most income in 2022. This is due to the fact that patients receiving treatment for ARS or cancer primarily obtain their anti-radiation medications from hospital pharmacies. Hospital pharmacists have the knowledge and tools necessary to give patients the appropriate anti-radiation medications and to keep track of their care.

Figure 1: Anti-Radiation Drugs Market, by Distribution channel, 2022 & 2032 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Anti-Radiation Drugs Regional Insights

By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The North America Anti-Radiation Drugs Market dominated this market in 2022 (45.80%). The nuclear power industry are active in both the United States and Canada. The existence of nuclear power plants, radiation-using research institutes, and healthcare facilities highlights the requirement for anti-radiation medications to safeguard local inhabitants and workers. Further, the U.S. Anti-radiation drugs market held the largest market share, and the Canada Anti-radiation drugs market was the fastest growing market in the North America region.

Further, the major countries studied in the market report are The U.S., Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 2: ANTI-RADIATION DRUGS MARKET SHARE BY REGION 2022 (USD Billion)

 Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe Anti-radiation drugs market accounts for the second-largest market share. Nuclear disasters like the Fukushima Daiichi catastrophe in Japan and the Chernobyl disaster in the Ukraine have occurred in a few European nations in the past. Due to these incidents, people are now more aware of the dangers of radiation exposure and the significance of having access to anti-radiation medications. Further, the German Anti-radiation drugs market held the largest market share, and the UK Anti-radiation drugs market was the fastest growing market in the European region.

The Asia-Pacific Anti-Radiation Drugs Market is expected to grow at the fastest CAGR from 2023 to 2032. Radiation-based medical procedures are frequently employed in diagnostic and cancer treatment procedures, and the Asia-Pacific area is a hub for medical tourism worldwide. Radiation exposure for radiation treatment patients, radiology, nuclear medicine, and oncology healthcare professionals is enhanced. This raises the demand for cutting-edge anti-radiation medications designed for use in medical settings. Moreover, China’s Anti-radiation drugs market held the largest market share, and the Indian Anti-radiation drugs market was the fastest growing market in the Asia-Pacific region.

Anti-Radiation Drugs Key Market Players & Competitive Insights

Leading market players are investing heavily in research and development in order to expand their product lines, which will help the Anti-radiation drugs market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their global footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, Anti-radiation drugs industry must offer cost-effective items.

Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the global Anti-radiation drugs industry to benefit clients and increase the market sector. In recent years, the Anti-radiation drugs industry has offered some of the most significant advantages to medicine. Major players in the Anti-radiation drugs market, including Amgen Inc., Anbex Inc., Arco Pharmaceuticals LLC, BTG International Inc., Cellphire, Inc., Chrysalis BioTherapeutics, Inc., Darnitsa, Enzychem Lifesciences Corporation, Humanetics Corporation, Mission Pharmacal Company, Myelo Therapeutics GmbH, Partner Therapeutics, Pluri Inc. and others, are attempting to increase market demand by investing in research and development operations.

Modern human pharmaceuticals are discovered, created, produced, and sold by a biotechnology company called Amgen Inc. (Amgen) to treat people with life-threatening disorders. It develops novel drugs in the therapeutic areas of cardiovascular disease, oncology/hematology, inflammation, bone health, neurological disorders, and nephrology. The company develops solutions using cutting-edge human genetics to investigate illness concerns and comprehend the fundamentals of human biology. Amgen mostly deals with US pharmaceutical wholesalers when selling its products. Additionally, it uses partnerships with other companies and direct-to-consumer platforms to market some products to clients directly. Australia, North America, Europe, the Middle East, and Asia-Pacific are among the regions where the firm operates. Amgen's headquarters are in Thousand Oaks, California, in the US.

Mission Pharmacal Co. is responsible for the development, manufacturing, and marketing of prescription, over-the-counter, and dietary supplement products. It offers remedies for conditions related to urology, dermatitis, and women's health, among other conditions. Additionally, it offers contract manufacturing services. Among the many formats in which Mission Pharmacal's products are made and distributed are powders, pills, solutions, creams, lotions, gels, and suspensions. The company serves both domestic and international markets through its network of sales and distribution. The company has warehouses and production, research and development facilities in Texas. The corporation is based in San Antonio, Texas, in the United States.

Key Companies in the Anti-radiation drugs market include

• Amgen Inc.


• Anbex Inc.


• Arco Pharmaceuticals LLC


• BTG International Inc.


• Cellphire, Inc.


• Chrysalis BioTherapeutics, Inc.


• Darnitsa


• Enzychem Lifesciences Corporation


• Humanetics Corporation


• Mission Pharmacal Company


• Myelo Therapeutics GmbH


• Partner Therapeutics


• Pluri Inc.

Anti-Radiation Drugs Industry Developments

February 2023: Amgen Inc. announced the African American Heart Study in collaboration with the Association of Black Cardiologists and the Morehouse School of Medicine to measure the association between Lipoprotein and atherosclerotic cardiovascular diseases in 5,000 African American individuals across the US.

Anti-Radiation Drugs Market Segmentation

Anti-radiation drugs Compound Outlook

• Potassium lodide (Kl)


• Prussian Blue


• DTPA (Diethylenetriamine Pentaacetate)


• Others

Anti-radiation drugs Application Outlook

• Acute Radiation Syndrome (ARS)


• Cancer Treatment


• Radiation Exposure


• Others

Anti-radiation drugs Distribution Channel Outlook

• Hospital Pharmacies


• Retail Pharmacies


• Others

Anti-radiation drugs Regional Outlook

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America